104530-79-2

Basic information

• Product Name: (S)-3-AMINOTETRAHYDROFURAN
• Synonyms: (S)-Tetrahydro-furan-3-ylamine;3-Furanamine,tetrahydro-, (3S)-;(S)-TETRAHYDROFURAN-3-AMINE;(S)-3-AMINOTETRAHYDROFURAN;(S)-3-Aminotetrahydrofuran tosylate;(S)-3-AMinotetrahydrofura...;(S)-(-)-3-AMinotetrahydrofuran p-toluenesulfonate salt;(3S)-oxolan-3-aMine
• CAS NO: 104530-79-2
• Molecular Formula: C₄H₉NO
• Molecular Weight: 87.12
• Product Categories: Chiral Compounds
• Mol File: 104530-79-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 125.6±33.0 °C(Predicted)
• Appearance: Off-white to brown/Crystalline Powder or Flakes
• Density: 0.997±0.06 g/cm3(Predicted)
• PKA: 8.90±0.20(Predicted)
• CAS DataBase Reference: (S)-3-AMINOTETRAHYDROFURAN(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-3-AMINOTETRAHYDROFURAN(104530-79-2)
• EPA Substance Registry System: (S)-3-AMINOTETRAHYDROFURAN(104530-79-2)

Safety Data

• RIDADR: UN1993
• Hazardous Substances Data: 104530-79-2(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

InChI:InChI=1/C7H8O3S.C4H9NO/c1-6-2-4-7(5-3-6)11(8,9)10;5-4-1-2-6-3-4/h2-5H,1H3,(H,8,9,10);4H,1-3,5H2/t;4-/m.0/s1

Upstream product

• 204512-95-8 (3S)-tetrahydrofuran-3-amine hydrochloride 
• 22929-52-8 tetrahydrofuran-3-one 

Downstream Products

• 1572510-58-7 N-(3,4-difluorophenyl)-3-[[(3S)-tetrahydrofuran-3-yl]sulfamoyl]benzamide 
• 1572510-42-9 N-(4-fluoro-3-methylphenyl)-3-[[(3S)-tetrahydrofuran-3-yl]sulfamoyl]benzamide 
• 1572516-28-9 2,6-difluoro-3-[[(3S)-tetrahydrofuran-3-yl]sulfamoyl]benzoic acid 
• 1572516-12-1 5-bromo-2-fluoro-6-methyl-3-[[(3S)-tetrahydrofuran-3-yl]sulfamoyl]benzoic acid 
• 1402391-08-5 C₂₈H₃₄BrN₅O₆ 
• 1280218-16-7 6-(2,4-difluorophenoxy)-8-methyl-2-[(S)-(tetrahydrofuran-3-yl)amino]-8H-pyrido[2,3-d]pyrimidin-7-one 

Relevant articles and documents

Widely applicable background depletion step enables transaminase evolution through solid-phase screening

Directed evolution of transaminases is a widespread technique in the development of highly sought-after biocatalysts for industrial applications. This process, however, is challenged by the limited availability of effective high-throughput protocols to evaluate mutant libraries. Here we report a rapid, reliable, and widely applicable background depletion method for solid-phase screening of transaminase variants, which was successfully applied to a transaminase from Halomonas elongata (HEWT), evolved through rounds of random mutagenesis towards a series of diverse prochiral ketones. This approach enabled the identification of transaminase variants in viable cells with significantly improved activity towards para-substituted acetophenones (up to 60-fold), as well as tetrahydrothiophen-3-one and related substrates. Rationalisation of the mutants was assisted by determination of the high-resolution wild-type HEWT crystal structure presented herein.

PURINE DERIVATIVES FOR USE IN THE TREATMENT OF ALLERGIC, INFLAMMATORY AND INFECTIOUS DISEASES

Compounds of formula (I): wherein R1 is C1-6alkylamino, or C1-6alkoxy; m is an integer having a value of 3, 4, or 5; n is an integer having a value of 0 to 3; p is an integer having a value of 1 or 2 and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases and cancer, and may also be useful as vaccine adjuvants.